Treatment of Advanced or Metastatic Mucosal Melanoma with KIT Mutation

Mucosal melanoma arising in an advanced, unresectable, or metastatic setting presents distinct molecular features from cutaneous melanoma. When a KIT mutation is identified, it defines a specific, actionable subgroup that warrants a tailored treatment approach.

Clinical Scenario

This protocol applies to patients with advanced, unresectable, or metastatic mucosal melanoma in whom molecular testing has confirmed a KIT mutation. Mucosal melanoma exhibits a higher KIT mutation rate than cutaneous melanoma, making routine molecular profiling essential to identify this targetable alteration.

Treatment Direction

The recommended approach for this population involves targeted therapy directed at the KIT alteration. The specific agent selection, sequencing, and management details are outlined in the full structured regimen.

Full regimen, dosing, and algorithm available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1200/EDBK-25-473858

MM exhibits a higher KIT mutation rate than CM, which may contribute to its greater responsiveness to KIT inhibitors than acral or sun-damaged melanomas.

the distinct genomic landscape of mucosal melanoma (MM; eg, KIT and NRAS mutations) underlines the need for routine molecular testing to identify actionable targets and tailor therapies, such as KIT inhibitors for KIT-mutant tumors or MEK inhibitors for NRAS-mutant cases.

View source ↗